title: Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic.
abstract: Despite the therapeutic potential of sphingolipids, the ability to develop this class of compounds as active pharmaceutical ingredients has been hampered by issues of solubility and delivery. Beyond these technical hurdles, significant challenges in completing the necessary preclinical studies to support regulatory review are necessary for commercialization. This review seeks to identify the obstacles and potential solutions in the translation of a novel liposomal technology from the academic bench to investigational new drug (IND) stage by discussing the preclinical development of the Ceramide NanoLiposome (CNL), which is currently being developed as an anticancer drug for the initial indication of hepatocellular carcinoma (HCC).
authors.forename: Mark
authors.initials: M
authors.lastname: Kester
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Bassler
authors.forename: Todd E
authors.initials: TE
authors.lastname: Fox
authors.forename: Carly J
authors.initials: CJ
authors.lastname: Carter
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Davidson
authors.forename: Mylisa R
authors.initials: MR
authors.lastname: Parette
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002518:Ceramides / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D008113:Liver Neoplasms / Q000188:drug therapy; D013107:Sphingolipids / Q000737:chemistry* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D002518:Ceramides; D008081:Liposomes; D013107:Sphingolipids; C101954:N-caproylsphingosine